In a survey of 1,226 people managing their weight, the ones who dropped more than a fifth of their body weight reported sagging skin nearly five times as often as the ones who lost less than a tenth. 72 percent versus 15 percent. The more weight came off, the more the skin, hair, and face seemed to pay for it.
That dose-response is the spine of a patient-reported survey published August 11 in Dermatology and Therapy ↗. The authors, a group of obesity-medicine physicians and dermatologists, sent an anonymous questionnaire to patients of a virtual cardio-kidney-metabolic program and sorted the 1,226 responses by how much body weight each person had lost and which drugs they were on. The drugs at the center of it are the GLP-1 receptor agonists, the class that includes semaglutide (sold as Ozempic ↗ and Wegovy) and tirzepatide (sold as Mounjaro ↗ and Zepbound), which mimic a gut hormone to blunt appetite. "Ozempic Face," the facial hollowing that made tabloids, is in the paper's title for a reason.
The cost climbs with the weight
The pattern held across four different complaints, and every one of them tracked with weight loss. Among people who lost more than 20 percent of their body weight, half reported decreased facial volume and a third reported feeling weaker. Step down to the 10-to-20-percent group and those numbers fell to 37 and 19 percent. Step down again to under 10 percent and they fell to 13 and 9 percent. Hair loss followed the same staircase, 52 percent at the top band down to 17 percent at the bottom. A Cochran-Armitage trend test, which checks whether a rate rises steadily across ordered groups, was significant for all four (p less than 0.001).
None of that is a surprise mechanistically. Rapid, large weight loss strips subcutaneous fat, and the face and the skin's underlying support go with it. The "reduced strength" line is the one worth flagging: it is the patient-felt version of the lean-mass loss that has dogged this drug class, the reason muscle preservation is now its own research beat.
The other side of the ledger
The same survey found the opposite effect on skin disease. Among respondents on at least one GLP-1 drug, a majority reported that preexisting inflammatory and hormonally driven skin conditions got better. Hidradenitis suppurativa, a painful chronic condition of abscesses in skin folds, improved in 13 of 15 people who had it (87 percent). Acanthosis nigricans, the velvety dark patches tied to insulin resistance, improved in 9 of 12 (75 percent). Psoriasis improved in 47 percent, acne in 41 percent, eczema in 27 percent.
Read the denominators before the percentages. Thirteen of fifteen is a strong-sounding number resting on fifteen people. These are small subgroups inside a survey, not a controlled trial of GLP-1 drugs for skin disease. But the direction is consistent with what is already understood: shedding fat lowers the low-grade inflammation and the insulin resistance that feed conditions like hidradenitis suppurativa and acanthosis nigricans. The same fat loss that hollows a cheek quiets an inflamed skin fold.
What the survey can and cannot say
This is self-reported data, and the design invites the obvious biases. The questionnaire was voluntary and anonymous, sent to patients of a single program, so people who noticed a change had more reason to answer and more reason to attribute it to the drug. Nobody examined a face or biopsied a plaque. The survey ties these effects to the magnitude of weight loss, not cleanly to any one drug, and it cannot separate the GLP-1 mechanism from the weight loss itself. There is no incidence rate a clinician could quote a patient, and no timeline for whether laxity or shedding recovers.
What it does deliver is scale and a clean gradient. Most of what the public knows about GLP-1 skin effects comes from before-and-after photos and single-clinic impressions. A 1,226-person gradient showing that the aesthetic downsides and the skin-disease upside both rise with the amount of weight lost is a sharper starting point, and the authors say as much: the mechanisms and the true incidence are the next studies to run.
The tradeoff is not really about the skin. It is about the weight, which is the GLP-1 receptor ↗'s whole job. Turn that lever far enough and both effects show up together. The patient deciding whether a hollow cheek is worth a clear one is weighing two consequences of the same result.